Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to
immune checkpoint inhibitors and has been shown to be more significantly associated with …

Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are
broadly efficacious, improved outcomes have been observed in patients with high PD-L1 …

microRNAs (miRs) are small RNAs that regulate gene expression at the posttranscriptional
level. It is anticipated that, in combination with transcription factors (TFs), they span a …

Advances in next-generation sequencing (NGS) promise to facilitate diagnosis of inherited
disorders. Although in research settings NGS has pinpointed causal alleles using …

FoundationOne ® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved
companion diagnostic test to identify patients who may benefit from treatment in …

Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can
provide a noninvasive method for detecting genomic biomarkers to guide clinical decision …

Objective: To evaluate the utility of targeted exome sequencing for the molecular diagnosis
of mitochondrial disorders, which exhibit marked phenotypic and genetic heterogeneity. …

In the context of a rolling mill case study, this paper presents a methodical framework based
on data mining for predicting the physical quality of intermediate products in interlinked …

Background: Atezo (anti–PD-L1) was FDA approved for 2L+ NSCLC based on results from
the randomized OAK and POPLAR trials, with atezo showing superior efficacy vs docetaxel (…

We used exome sequencing to identify mutations in sideroflexin 4 (SFXN4) in two children
with mitochondrial disease (the more severe case also presented with macrocytic anemia). …